Invivyd, Inc. (NASDAQ:IVVD) Short Interest Update

Invivyd, Inc. (NASDAQ:IVVD - Get Free Report) was the target of a significant increase in short interest in the month of January. As of January 31st, there was short interest totalling 6,620,000 shares, an increase of 5.2% from the January 15th total of 6,290,000 shares. Approximately 8.8% of the shares of the company are sold short. Based on an average daily volume of 12,710,000 shares, the short-interest ratio is presently 0.5 days.

Insider Activity

In other news, Director Terrance Mcguire sold 150,000 shares of the business's stock in a transaction that occurred on Monday, December 9th. The stock was sold at an average price of $0.61, for a total value of $91,500.00. Following the transaction, the director now owns 4,538,079 shares of the company's stock, valued at approximately $2,768,228.19. The trade was a 3.20 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Over the last 90 days, insiders have sold 816,466 shares of company stock valued at $423,214. Company insiders own 17.90% of the company's stock.

Hedge Funds Weigh In On Invivyd

Several large investors have recently added to or reduced their stakes in IVVD. Proficio Capital Partners LLC acquired a new stake in Invivyd during the third quarter worth about $27,000. Jane Street Group LLC increased its stake in Invivyd by 290.5% during the fourth quarter. Jane Street Group LLC now owns 117,432 shares of the company's stock worth $52,000 after acquiring an additional 87,358 shares during the last quarter. Barclays PLC increased its stake in Invivyd by 7.8% during the fourth quarter. Barclays PLC now owns 127,180 shares of the company's stock worth $56,000 after acquiring an additional 9,207 shares during the last quarter. Renaissance Technologies LLC acquired a new stake in Invivyd during the fourth quarter worth about $74,000. Finally, JPMorgan Chase & Co. increased its stake in Invivyd by 644.1% during the fourth quarter. JPMorgan Chase & Co. now owns 256,900 shares of the company's stock worth $114,000 after acquiring an additional 222,375 shares during the last quarter. 70.36% of the stock is currently owned by hedge funds and other institutional investors.

Invivyd Stock Performance

NASDAQ IVVD traded down $0.19 during trading hours on Thursday, hitting $1.21. 3,623,060 shares of the company's stock were exchanged, compared to its average volume of 24,825,070. The business's 50 day moving average is $0.75 and its 200-day moving average is $0.86. Invivyd has a 12-month low of $0.35 and a 12-month high of $4.74. The firm has a market capitalization of $144.74 million, a P/E ratio of -0.62 and a beta of 0.61.

Analysts Set New Price Targets

IVVD has been the topic of a number of recent research reports. Morgan Stanley dropped their target price on Invivyd from $9.50 to $3.55 and set an "overweight" rating on the stock in a report on Wednesday, November 20th. HC Wainwright reissued a "buy" rating and issued a $10.00 target price on shares of Invivyd in a report on Tuesday, February 4th. EF Hutton Acquisition Co. I raised Invivyd to a "strong-buy" rating in a report on Wednesday, October 30th. Finally, D. Boral Capital reissued a "buy" rating and issued a $9.00 target price on shares of Invivyd in a report on Monday, February 3rd. Four research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Buy" and an average price target of $7.89.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.